

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 June 2024 (06.06.2024)



(10) International Publication Number
WO 2024/118987 A1

(51) International Patent Classification:
A61K 31/5517 (2006.01) *A61P 25/08* (2006.01)

(21) International Application Number:
PCT/US2023/081942

(22) International Filing Date:
30 November 2023 (30.11.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/429,755 02 December 2022 (02.12.2022) US
63/589,283 10 October 2023 (10.10.2023) US

(71) Applicant: **ARENA PHARMACEUTICALS, INC.**
[US/US]; 66 Hudson Boulevard East, New York, New York
10007-2192 (US).

(72) Inventors: **OREVILLO, Chadwick J.**; c/o Longboard
Pharmaceuticals, Inc., 4275 Executive Square, Suite 950, La
Jolla, California 92037 (US). **KAYE, Randall**; c/o Long-

board Pharmaceuticals, Inc., 4275 Executive Square, Suite
950, La Jolla, California 92037 (US). **SRINIVAS, Nugge-**
halli; c/o Longboard Pharmaceuticals, Inc., 4275 Executive
Square, Suite 950, La Jolla, California 92037 (US).

(74) Agent: **DYAR, Scott** et al.; P.O. Box 1022, Minneapolis,
55440-1022 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(54) Title: METHODS OF TREATMENT




FIG. 17

(57) Abstract: Provided herein are treatment methods including administering a 5-hydroxytryptamine (HT)_{2C} receptor agonist to a patient in need thereof. An exemplary method includes treating or preventing a 5-hydroxytryptamine (HT)_{2C} receptor-associated disorder in a patient in need thereof, wherein the method comprises administering to the patient (*R*)-N-(2,2-difluoroethyl)-7-methyl-1,2,3,4,6,7-hexahydro-[1,4]diazepino[6,7,1-*hi*]indole-8-carboxamide (Compound 1), or a pharmaceutically acceptable salt thereof, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered twice daily.

[Continued on next page]



WO 2024/118987 A1

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))